BioVie Inc. BIVI · Stock Open BioVie Inc. in new tab
Analyst price targets
Recent rating changes, newest first
BioVie Inc. Analysis (BIVI)
Is BioVie Inc. a good investment? BioVie Inc. (BIVI) is currently trading at 1.34 USD. Market analysts have a consensus price target of 5.26 USD. This suggests a potential upside from current levels.
Earnings Schedule: BioVie Inc. is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -0.57.
Investor FAQ
Does BioVie Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is BioVie Inc.?
BioVie Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -3.05.
Company Profile
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 22, 2019 | 1:100 |
| Aug. 6, 2024 | 1:10 |
| July 7, 2025 | 1:10 |
Community Discussion